
Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.
Invest in next-gen health screening, today
Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.

Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.
Invest in next-gen health screening, today
Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.

Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.
Invest in next-gen health screening, today
Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.
Revealia™ leverages mRNA-based screening to provide early insights of potential health risks.
Revealia™ leverages mRNA-based screening to provide early insights of potential health risks.
leading the future of Cancer Screening




Patent Protected Technology
Patent Protected Technology




Experienced Leadership Team
Experienced Leadership Team




Over 3,600 Patient Samples Collected
Over 3,600 Patient Samples Collected
Nanoscale Technology + AI Insights = Groundbreaking Results
Nanoscale Technology + AI Insights = Groundbreaking Results
Innovative screening
Innovative screening
Our advanced nanoscale technology and AI analyze mRNA from a simple cheek swab, offering insights into a broad range of potential health risks, including various cancers and inflammatory conditions.
Over 3,600 Patient Samples Collected
Over 3,600 Patient Samples Collected
These samples were collected in 40 clinics in the United States according to an IRB approved clinical protocol.
World Renowned Research
World Renowned Research
Hundreds of peer-reviewed articles in renowned publications support our scientific breakthrough.



Pioneering Excellence in Product Development
Pioneering Excellence in Product Development
Cheek Swab Technology
Cheek swabs are a convenient, non-invasive method to collect cells for genetic analysis.
1
Cheek Swab Technology
Cheek swabs are a convenient, non-invasive method to collect cells for genetic analysis.
1
Cheek Swab Technology
Cheek swabs are a convenient, non-invasive method to collect cells for genetic analysis.
1
Powerful IP Protection
In 2022, our PCT Patent Pending covers a uniquely designed chip featuring 48 mRNA bio-markers, combined with our cheek swab for nanoscale screening.
2
Powerful IP Protection
In 2022, our PCT Patent Pending covers a uniquely designed chip featuring 48 mRNA bio-markers, combined with our cheek swab for nanoscale screening.
2
Powerful IP Protection
In 2022, our PCT Patent Pending covers a uniquely designed chip featuring 48 mRNA bio-markers, combined with our cheek swab for nanoscale screening.
2
Top Rated Results Lab
Our lab has the coveted and highest possible ratings with both CLIA and CAP certifications.
3
Top Rated Results Lab
Our lab has the coveted and highest possible ratings with both CLIA and CAP certifications.
3
Top Rated Results Lab
Our lab has the coveted and highest possible ratings with both CLIA and CAP certifications.
3
Medical Science + Al Expertise
Co-founder, is a renowned physician and scientist with a legacy of 56 years of accomplishments and successes in the field of medical science and biotechnology.
4
Medical Science + Al Expertise
Co-founder, is a renowned physician and scientist with a legacy of 56 years of accomplishments and successes in the field of medical science and biotechnology.
4
Medical Science + Al Expertise
Co-founder, is a renowned physician and scientist with a legacy of 56 years of accomplishments and successes in the field of medical science and biotechnology.
4
Our team is made up of leading experts in health, experienced AI technologists, and skilled operators. A CAP CLIA certified lab collects, validates and analyzes our extensive and growing patient samples.
Explore our progress and future goals. Milestones achieved, including research, development, and product rollout.
Explore our progress and future goals. Milestones achieved, including research, development, and product rollout.
IP Protection
2022
Uplisting will help scale advertising and expand disease screening capabilities.
Patents pending on nanoscale signals our Al can use to detect many types of cancer and other progressive diseases
Invented Al driven process gets nanogram quantities of cancer signals effectively analyzed for diagnostics
Over 3,000 people have already taken our cheek-swab test
Brand revamp for direct-to- consumer cheek-swab test.
2023
Testing
2025
Uplist + Launch
Rebranding
2024
Invention
2019
Invention
Invented Al driven process gets nanogram quantities of cancer signals effectively analyzed for diagnostics
Invented Al driven process gets nanogram quantities of cancer signals effectively analyzed for diagnostics
IP Protection
Patents pending on nanoscale signals our Al can use to detect many types of cancer and other progressive diseases
Patents pending on nanoscale signals our Al can use to detect many types of cancer and other progressive diseases
Testing
Over 3,000 people have already taken our cheek-swab test
Over 3,000 people have already taken our cheek-swab test
Launch
Rebranding
Rebranding
October launch for direct-to- consumer cheek-swab test.
Brand revamp for direct-to- consumer cheek-swab test.
Brand revamp for direct-to- consumer cheek-swab test.
Uplist + Scale
Uplist + Launch
Uplist + Launch
Uplisting will help scale advertising and expand disease screening capabilities.
Uplisting will help scale advertising and expand disease screening capabilities.
Why invest in Revealia?
Why invest in Revealia?



01
Growing home screening market
02
First-mover advantage with RNA-focused tests






03
Clear path to Scalablity
Contact Us
Contact Us
Contact Us
Learn more about our journey and investment opportunities.
Learn more about our journey and investment opportunities.
Learn more about our journey and investment opportunities.


